医薬品有効成分（API）の世界市場 - 薬剤タイプ（ジェネリック、革新的）、合成（合成、バイオテクノロジー）、用途別、地域別、国別の分析（2021年版）。COVID-19の影響を考慮した市場インサイトと予測（2021年～2026年）

Global Active Pharmaceutical Ingredient (API) Market – Analysis By Drug Type (Generic, Innovative), Synthesis (Synthetic, Biotech), By Application, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)

エグゼクティブサマリー世界の医薬品有効成分（API）市場は、2020年に1,796億米ドルと評価されました。医薬品有効成分市場の成長機会は、高齢者人口の増加、技術進歩の高まり、世界におけるAPI製造施設の増加... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2021年12月31日	US$2,400 シングルユーザーライセンスライセンス・価格情報注文方法はこちら	230	英語

サマリー

エグゼクティブサマリー

世界の医薬品有効成分（API）市場は、2020年に1,796億米ドルと評価されました。医薬品有効成分市場の成長機会は、高齢者人口の増加、技術進歩の高まり、世界におけるAPI製造施設の増加、グローバルプラットフォームにおける主要な市場プレイヤーのいくつかによる研究開発活動の増加に起因しています。

また、新薬開発への投資だけでなく、認知度の向上も、世界における臨床試験の数を押し上げ、原薬市場を牽引しています。COVID-19の発生による呼吸器疾患の有病率の上昇に伴い、新薬の需要が増えることが予想され、それが原薬の需要を押し上げ、結果的に世界の原薬市場に影響を与える可能性が高いです。

バイオ製薬会社は、新しい技術へのアクセス、市場領域の拡大、臨床試験や投資のための資金を増やすために、M&Aを選択しています。API市場は過去数年間、目覚しい成長を遂げてきました。この成長傾向は、今後もアジア太平洋地域の需要増加により継続すると予測されます。これは主に、膨大な人口とそれに伴う感染症の発生により、治療薬を必要とする中国、インド、日本が牽引しています。

さらに、死者数の増加やウイルスの蔓延により、多くの製薬会社、バイオ医薬品会社、小規模な新興企業が協力し、ウイルスと戦うための効果的な医薬品を開発するようになったのです。世界中の科学者たちが、COVID-19を効果的に標的とする分子を発見したのです。現在、155の分子が臨床研究中であり、45の分子がCOVID-19を標的とする前臨床開発中です。企業はそのような時に、研究参加者、スタッフ、従業員の安全を守るために、現地で監視を行いました。

報告書の範囲

- このレポートは医薬品有効成分市場を金額（10億米ドル）別に分析したものです。

- 原薬市場を用途別（腫瘍、循環器、糖尿病、神経、その他）に分析したレポートです。

- 医薬品原薬市場を薬剤タイプ別（ジェネリック原薬、革新的原薬）に分析したレポートです。

- 原薬市場を合成別（合成、バイオ）に分析した報告書

- 世界の医薬品原薬市場は地域別（北米、欧州、アジア太平洋、LAMEA）に分析されています。

- 世界の医薬品原料市場は国別（米国、カナダ、ドイツ、フランス、イギリス、イタリア、スペイン、中国、日本、インド）に分析されています。

- 市場の魅力は、地域別、用途別、薬物タイプ別、合成別で提示されています。

- また、業界の主な機会、動向、ドライバー、課題についても分析されています。

- 本レポートでは、競合他社の動向、戦略、M&A、新製品開発などを追跡しています。

- 本レポートで分析対象とする企業は、ファイザー社、グラクソ・スミスクライン社、アッヴィ社、ノバルティス社、イーライリリー・アンド・カンパニー社、メルクKGaA社、テバ・ファーマスーティカル・インダストリーズ社、サノフィ社、ブリストル・マイヤーズスクイブ社、ベーリンガーインゲルハイム社などです。

- 本レポートでは、2016年～2020年の過去期間と2021年～2026年の予測期間における医薬品原薬市場の分析結果をご紹介しています。

主な対象読者

- 医薬品原薬メーカー

- 製薬会社

- コンサルティング・アドバイザリーファーム

- 政府・政策担当者

- 規制当局

ページTOPに戻る

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Global Active Pharmaceutical Ingredient Market: Product Outlook

4. Global Active Pharmaceutical Ingredient Market: Size and Forecast

4.1 Global Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026

5. Global Active Pharmaceutical Ingredient Market Segmentation – By Application, By Drug Type, By Synthesis

5.1 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Application

5.1.1 Oncology – Market Size and Forecast (2016-2026)

5.1.2 Cardiology– Market Size and Forecast (2016-2026)

5.1.3 Diabetes – Market Size and Forecast (2016-2026)

5.1.4 Neurology – Market Size and Forecast (2016-2026)

5.1.5 Others – Market Size and Forecast (2016-2026)

5.2 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Drug Type

5.2.1 Generic API– Market Size and Forecast (2016-2026)

5.2.2 Innovative API – Market Size and Forecast (2016-2026)

5.3 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Synthesis

5.3.1 Synthetic – Market Size and Forecast (2016-2026)

5.3.2 Biotech – Market Size and Forecast (2016-2026)

6. Global Active Pharmaceutical Ingredient Market: Regional Analysis

6.1 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Region

7. North America Active Pharmaceutical Ingredient Market: An Analysis (2016-2026)

7.1 North America Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026)

7.2 North America Active Pharmaceutical Ingredient Market – Prominent Companies

7.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)

7.4 Market Segmentation By Drug Type (Generic API and Innovative API)

7.5 Market Segmentation By Synthesis (Synthetic and Biotech)

7.6 North America Active Pharmaceutical Ingredient Market: Country Analysis

7.7 Market Opportunity Chart of North America Active Pharmaceutical Ingredient Market - By Country, By Value, 2026

7.8 Competitive Scenario of North America Active Pharmaceutical Ingredient Market: By Country

7.9 United States Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

7.10 United States Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

7.11 Canada Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

7.12 Canada Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

8. Europe Active Pharmaceutical Ingredient Market: An Analysis (2016-2026)

8.1 Europe Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

8.2 Europe Active Pharmaceutical Ingredient Market – Prominent Companies

8.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)

8.4 Market Segmentation By Drug Type (Generic API and Innovative API)

8.5 Market Segmentation By Synthesis (Synthetic and Biotech)

8.6 Europe Active Pharmaceutical Ingredient Market: Country Analysis

8.7 Market Opportunity Chart of Europe Active Pharmaceutical Ingredient Market - By Country, By Value, 2026

8.8 Competitive Scenario of Europe Active Pharmaceutical Ingredient Market: By Country

8.9 Germany Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

8.10 Germany Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

8.11 United Kingdom Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

8.12 United Kingdom Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

8.13 France Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

8.14 France Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

8.15 Spain Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

8.16 Spain Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

8.17 Italy Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

8.18 Italy Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

9. Asia Pacific Active Pharmaceutical Ingredient Market: An Analysis (2016-2026)

9.1 Asia Pacific Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

9.2 Asia Pacific Active Pharmaceutical Ingredient Market – Prominent Companies

9.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)

9.4 Market Segmentation By Drug Type (Generic API and Innovative API)

9.5 Market Segmentation By Synthesis (Synthetic and Biotech)

9.6 Asia Pacific Active Pharmaceutical Ingredient Market: Country Analysis

9.7 Market Opportunity Chart of Asia Pacific Active Pharmaceutical Ingredient Market - By Country, By Value, 2026

9.8 Competitive Scenario of Asia Pacific Active Pharmaceutical Ingredient Market: By Country

9.9 China Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

9.10 China Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

9.11 Japan Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

9.12 Japan Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

9.13 India Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value

9.14 India Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)

10. Global Active Pharmaceutical Ingredient Market Dynamics

10.1 Drivers

10.2 Restraints

10.3 Trends

11. Market Attractiveness

11.1 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market – By Application, 2026

11.2 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Drug Type, 2026

11.3 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Synthesis, 2026

11.4 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Region, 2026

12. Competitive Landscape

12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers

12.2 Market Share Analysis

13. Company Analysis

13.1 Pfizer Inc.,

13.2 GlaxoSmithKline

13.3 AbbVie Inc.

13.4 Novartis AG

13.5 Eli Lilly and Company

13.6 Merck KGaA

13.7 Teva Pharmaceutical Industries Ltd.

13.8 Sanofi

13.9 Bristol-Myers Squibb

13.10 Boehringer Ingelheim

List of Figures

Figure 1: Global Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 2: Percentage of API manufacturing facilities for all drugs (August 2019)

Figure 3: World’s leading causes of death (in millions), 2019

Figure 4: World Population 65 Years & Above (% of Total), 2015-2019

Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 6: Estimated number of new cases in 2020, worldwide, both sexes, all ages

Figure 7: Global Active Pharmaceutical Ingredient Market-By Application Market Share, 2020 & 2026

Figure 8: Global Active Pharmaceutical Ingredient Market- By Oncology, By Value (USD Billion), 2016-2026

Figure 9: Global Active Pharmaceutical Ingredient Market- By Cardiology, By Value (USD Billion), 2016-2026

Figure 10: Global Active Pharmaceutical Ingredient Market- By Diabetes, By Value (USD Billion), 2016-2026

Figure 11: Global Active Pharmaceutical Ingredient Market- By Neurology, By Value (USD Billion), 2016-2026

Figure 12: Global Active Pharmaceutical Ingredient Market- By Others, By Value (USD Billion), 2016-2026

Figure 13: Global Active Pharmaceutical Ingredient Market- By Drug Type Market Share, 2020 & 2026

Figure 14: Global Active Pharmaceutical Ingredient Market- By Generic API, By Value (USD Billion), 2016-2026

Figure 15: Global Active Pharmaceutical Ingredient Market- By Innovative API, By Value (USD Billion), 2016-2026

Figure 16: Global Active Pharmaceutical Ingredient Market- By Synthesis Market Share, 2020 & 2026

Figure 17: Global Active Pharmaceutical Ingredient Market- By Synthetic, By Value (USD Billion), 2016-2026

Figure 18: Global Active Pharmaceutical Ingredient Market- By Biotech, By Value (USD Billion), 2016-2026

Figure 19: Global Active Pharmaceutical Ingredient Market- By Region Market Share, 2020 & 2026

Figure 20: North America Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 21: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 22: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 23: North America Urban population, 2015-2018 (In %)

Figure 24: North America Active Pharmaceutical Ingredient players market share (%), 2020

Figure 25: North America Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 26: North America Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 27: North America Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 28: Market Opportunity Chart of North America Active Pharmaceutical Ingredient Market- By Country, By Value (Year 2016-2026)

Figure 29: North America Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026

Figure 30: United States Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 31: United State year-on-year growth of Active Pharmaceutical Ingredient (in %), (2017-2026)

Figure 32: United State population aged 65 and above, (in % of total population), 2016-2020

Figure 33: United State health expenditure (% of GDP), 2013-2018

Figure 34: United State Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 35: United State Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 36: United State Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 37: Canada Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 38: Canada population aged 65 and above (% of total population), 2016-2020

Figure 39: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 40: Canada Urban population, 2015-2019 (In %)

Figure 41: Canada Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 42: Canada Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 43: Canada Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 44: Europe Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 45: Europe current health expenditure (% of GDP), (2014-2018)

Figure 46: Europe population aged 65 and above (% of total population), 2020

Figure 47: Europe percentage of dying between age 30 to 70 from any cardiovascular disease, cancer, diabetes and chronic respiratory disease, 2019

Figure 48: Europe Active Pharmaceutical Ingredient players market share (%), 2020

Figure 49: Europe Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 50: Europe Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 51: Europe Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 52: Market Opportunity Chart of Europe Active Pharmaceutical Ingredient Market- By Country, By Value (Year 2016-2026)

Figure 53: Europe Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026

Figure 54: Germany Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 55: Germany current health expenditure (% of GDP), (2014-2018)

Figure 56: Germany population aged 65 and above (% of total population), 2016-2020

Figure 57: Germany urban population (% of total population), 2016-2019

Figure 58: Germany Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 59: Germany Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 60: Germany Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 61: United Kingdom Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 62: United Kingdom current health expenditure (% of GDP), (2014-2018)

Figure 63: United Kingdom population aged 65 and above (% of total population), 2016-2020

Figure 64: United Kingdom urban population (in millions), 2016-2020

Figure 65: United Kingdom Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 66: United Kingdom Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 67: United Kingdom Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 68: France Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 69: France current health expenditure (% of GDP), (2014-2018)

Figure 70: France urban population (% of total population), 2016-2020

Figure 71: France population aged 65 and above (% of total population), 2016-2020

Figure 72: France Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 73: France Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 74: France Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 75: Spain Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 76: Spain current health expenditure (% of GDP), (2014-2018)

Figure 77: Spain population aged 65 and above (% of total population), 2016-2020

Figure 78: Spain urban population (% of total population), 2016-2020

Figure 79: Spain Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 80: Spain Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 81: Spain Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 82: Italy Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 83: Italy current health expenditure (% of GDP), (2014-2018)

Figure 84: Italy population aged 65 and above (% of total population), 2016-2020

Figure 85: Italy urban population (% of total population), 2016-2020

Figure 86: Italy Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 87: Italy Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 88: Italy Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 89: Asia Pacific Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 90: Asia Pacific urban population (% of total population), 2016-2020

Figure 91: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 92: Asia Pacific population aged 65 years and above (% of total population), 2016-2020

Figure 93: Asia Pacific Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 94: Asia Pacific Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 95: Asia Pacific Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 96: Market Opportunity Chart of APAC Active Pharmaceutical Ingredient Market- By Country, By Value (Year-2026)

Figure 97: APAC Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026

Figure 98: China Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 99: China total population in billions, 2016-2020

Figure 100: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 101: China export destinations of Active Pharmaceutical Ingredient, 2019

Figure 102: China Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 103: China Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 104: China Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 105: Japan Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 106: Japan population above 65 years (% of total population), 2016-2020

Figure 107: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)

Figure 108: Japan urban population (in millions), 2016-2020

Figure 109: Japan Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 110: Japan Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 111: Japan Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026

Figure 112: India Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)

Figure 113: India Current Healthcare Expenditure (% of GDP), 2015-2018

Figure 114: India population (in billions), 2016-2020

Figure 115: India urban population (% of total population), 2015-2019

Figure 116: India Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026

Figure 117: India Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026

Figure 118: India Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Million), 2016-2026

Figure 119: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Application (Year-2016-2026)

Figure 120: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Drug Type (Year 2016-2026)

Figure 121: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Synthesis (Year 2016-2026)

Figure 122: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Region (Year 2016-2026)

Figure 123: Global Active Pharmaceutical Ingredient players market share (%), 2020

Figure 124: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020

Figure 125: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020

Figure 126: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020

Figure 127: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020

Figure 128: GlaxoSmithKline Gross Profit (USD Million), 2016-2020

Figure 129: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020

Figure 130: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020

Figure 131: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020

Figure 132: AbbVie Inc. Net Income (USD Million), 2016-2020

Figure 133: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020

Figure 134: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020

Figure 135: Novartis Annual Sales Revenue (USD Million), 2016-2020

Figure 136: Novartis Annual Net Income/Loss (USD Million), 2016-2020

Figure 137: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020

Figure 138: Novartis Sales Revenue Split, By Geography Segment (%), FY2020

Figure 139: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020

Figure 140: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020

Figure 141: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020

Figure 142: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020

Figure 143: Merck KGaA Sales Revenues, 2016-2020 (USD Million)

Figure 144: Merck KGaA Gross Profit, 2016-2020 (USD Million)

Figure 145: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020

Figure 146: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020

Figure 147: Teva Pharmaceutical Industries Ltd. Sales Revenues, 2016-2020 (USD Million)

Figure 148: Teva Pharmaceutical Industries Ltd. Net Income, 2016-2020 (USD Million)

Figure 149: Teva Pharmaceutical Industries Ltd. sales Revenues, By Business Segment (%) in North America, FY2020

Figure 150: Teva Pharmaceutical Industries Ltd. sales Revenue, By Geographical Segment (%), FY2020

Figure 151: Sanofi Sales Revenues, 2016-2020 (USD Million)

Figure 152: Sanofi Gross Profit, 2016-2020 (USD Million)

Figure 153: Sanofi Sales Revenue Split, By Business Segment (%), FY2020

Figure 154: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020

Figure 155: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)

Figure 156: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)

Figure 157: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020

Figure 158: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020

Figure 159: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)

Figure 160: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)

Figure 161: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020

Figure 162: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020

ページTOPに戻る

Table of Contents

Summary

Executive Summary

The global Active Pharmaceutical Ingredients (API) Market was valued at USD 179.6 Billion in the year 2020. Growth opportunities for the Active Pharmaceutical Ingredient market is attributed to the growth of the geriatric population, rising technical advancements, increasing API manufacturing facilities in the world and increasing number of research and development activities by some of the key market players in the global platform.

Additionally, growing awareness, as well as investments in the development of new drugs in the market, is pushing the number of clinical trials in the world which is driving the Active Pharmaceutical Ingredient market. With the rising prevalence of respiratory diseases due to the outbreak of COVID-19, it is expected that there will be more demand for new drugs which is likely to push the demand for API and consequently affect the Global Active Pharmaceutical Market in the world.

The biopharma companies are opting for mergers and acquisitions to gain access to new technologies, expand their market area and increase their capital for clinical trials and investments. The API market has been witnessing impressive growth over the past few years. This growth trend is projected to continue due to the increase in demand from the Asia Pacific region in the future. This is mainly driven by China, India and Japan which consist of a huge population and thereby huge incidence of infectious diseases which require medicines for treatment.

Furthermore, the rising death toll and spread of the virus prompted many pharmaceutical companies, biopharmaceutical companies and small start-ups to collaborate and bring out effective medicine to fight the same. Scientists all over the world found molecules that can effectively target COVID-19. Currently, 155 molecules are under clinical investigation, and 45 molecules are under preclinical development to be targeted against COVID-19. Companies monitored locally to protect the safety of study participants, staff and employees during such times.

Scope of the Report

• The report analyses the Active Pharmaceutical Ingredients Market by Value (USD Billion)

• The report analyses the Active Pharmaceutical Ingredients Market by Application (Oncology, Cardiology, Diabetes, Neurology, Others).

• The report analyses the Active Pharmaceutical Ingredients Market by Drug Type (Generic API, Innovative API)

• The report analyses the Active Pharmaceutical Ingredients Market by Synthesis (Synthetic, Biotech)

• The Global Active Pharmaceutical Ingredients Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA).

• The Global Active Pharmaceutical Ingredients Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India).

• The attractiveness of the market has been presented by region, by Application, by Drug Type and by Synthesis.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

• The companies analysed in the report include Pfizer Inc., GlaxoSmithKline, AbbVie Inc., Novartis AG, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sanofi, Bristol-Myers Squibb and Boehringer Ingelheim.

• The report presents the analysis of the Active Pharmaceutical Ingredients market for the historical period of 2016-2020 and the forecast period of 2021-2026.

Key Target Audience

• Active Pharmaceutical Ingredients Manufacturers

• Pharmaceutical Companies

• Consulting and Advisory Firms

• Government and Policy Makers

• Regulatory Authorities

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（薬学的薬物）の最新刊レポート

皮膚科治療薬市場レポート：2024-2034

Azoth Analytics社のその他分野での最新刊レポート

本レポートと同じKEY WORD（active pharmaceutical）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

医薬品有効成分（API）の世界市場 - 薬剤タイプ（ジェネリック、革新的）、合成（合成、バイオテクノロジー）、用途別、地域別、国別の分析（2021年版）。COVID-19の影響を考慮した市場インサイトと予測（2021年～2026年）

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（薬学的薬物）の最新刊レポート

Azoth Analytics社のその他分野での最新刊レポート

本レポートと同じKEY WORD（active pharmaceutical）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?